title: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
abstract: The molecular mechanisms by which tumor cells metastasize to bone are likely to involve invasion, cell adhesion to bone, and the release of soluble mediators from tumor cells that stimulate osteoclast-mediated bone resorption. Bisphosphonates (BPs) are powerful inhibitors of the osteoclast activity and are, therefore, used in the treatment of patients with osteolytic metastases. However, an added beneficial effect of BPs may be direct antitumor activity. We previously reported that BPs inhibit breast and prostate carcinoma cell adhesion to bone (Boissier et al., Cancer Res., 57: 3890-3894, 1997). Here, we provided evidence that BP pretreatment of breast and prostate carcinoma cells inhibited tumor cell invasion in a dose-dependent manner. The order of potency for four BPs in inhibiting tumor cell invasion was: zoledronate > ibandronate > NE-10244 (active pyridinium analogue of risedronate) > clodronate. In addition, NE-58051 (the inactive pyridylpropylidene analogue of risedronate) had no inhibitory effect, whereas NE-10790 (a phosphonocarboxylate analogue of risedronate in which one of the phosphonate groups is substituted by a carboxyl group) inhibited tumor cell invasion to an extent similar to that observed with NE-10244, indicating that the inhibitory activity of BPs on tumor cells involved the R2 chain of the molecule. BPs did not induce apoptosis in tumor cells, nor did they inhibit tumor cell migration at concentrations that did inhibit tumor cell invasion. However, although BPs did not interfere with the production of matrix metalloproteinases (MMPs) by tumor cells, they inhibited their proteolytic activity. The inhibitory effect of BPs on MMP activity was completely reversed in the presence of an excess of zinc. In addition, NE-10790 did not inhibit MMP activity, suggesting that phosphonate groups of BPs are responsible for the chelation of zinc and the subsequent inhibition of MMP activity. In conclusion, our results provide evidence for a direct cellular effect of BPs in preventing tumor cell invasion and an inhibitory effect of BPs on the proteolytic activity of MMPs through zinc chelation. These results suggest, therefore, that BPs may be useful agents for the prophylactic treatment of patients with cancers that are known to preferentially metastasize to bone.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale Research Unit 403, Faculté de Médecine Laënnec, Lyon, France.
authors.forename: S
authors.initials: S
authors.lastname: Boissier
authors.forename: M
authors.initials: M
authors.lastname: Ferreras
authors.forename: O
authors.initials: O
authors.lastname: Peyruchaud
authors.forename: S
authors.initials: S
authors.lastname: Magnetto
authors.forename: F H
authors.initials: FH
authors.lastname: Ebetino
authors.forename: M
authors.initials: M
authors.lastname: Colombel
authors.forename: P
authors.initials: P
authors.lastname: Delmas
authors.forename: J M
authors.initials: JM
authors.lastname: Delaissé
authors.forename: P
authors.initials: P
authors.lastname: Clézardin
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis; D001859:Bone Neoplasms / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002448:Cell Adhesion; D002453:Cell Cycle / Q000187:drug effects; D002465:Cell Movement; D004002:Clodronic Acid / Q000494:pharmacology; D003094:Collagen / Q000378:metabolism; D004164:Diphosphonates / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005434:Flow Cytometry; D005470:Fluorometry; D006801:Humans; D000077557:Ibandronic Acid; D007093:Imidazoles / Q000494:pharmacology; D007797:Laminin / Q000378:metabolism; D008297:Male; D020782:Matrix Metalloproteinases / Q000378:metabolism; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011509:Proteoglycans / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D011726:Pyridinium Compounds / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D015032:Zinc / Q000378:metabolism; D000077211:Zoledronic Acid
chemical_list: C410028:2-(3-pyridinyl)-1-hydroxyethylidene-1,1-phosphonocarboxylic acid; D000972:Antineoplastic Agents, Phytogenic; D004164:Diphosphonates; D004338:Drug Combinations; D007093:Imidazoles; D007797:Laminin; D011509:Proteoglycans; D011725:Pyridines; D011726:Pyridinium Compounds; D004002:Clodronic Acid; C108384:NE 58051; C059485:matrigel; C108383:NE 10244; D000077211:Zoledronic Acid; D003094:Collagen; D020782:Matrix Metalloproteinases; D015032:Zinc; D017239:Paclitaxel; D000077557:Ibandronic Acid